Effects of perioperative ERAS pathway management VS traditional management on clinical outcomes in laparoscopic-assisted radical resection of distal gastric cancer The GISSG18-01 Randomized Clinical Trial

• DOI: 10.21203/rs.2.24696/v1
• Publication Date: 2020-02-27T16:34:47Z
• Authors: Yulong Tian; Shougen Cao; Leping Li; Qingsi He; Lijian Xia; Lixin Jiang; Yinlu Ding; Xinjian Wang; Hao Wang; Weizheng Mao; Xizeng Hui; Yiran Shi; Huanhu Zhang; Xianqun Chu; Henrik Kehlet; Yanbing Zhou
• Keywords: Clinical endpoint; Regimen

Abstract Background: As well known, the incidence of gastric cancer in East Asian countries is much higher than international average. Therefore, improving prognosis patients and establishing effective clinical pathways are important topics for prevention treatment cancer. At present, enhanced recovery after surgery (ERAS) pathway widely used field surgery. Many RCT studies have proven that ERAS regimen can not improve short-term outcomes patients. However, a prospective study on effect has been reported. This trial aims to confirm whether disease-free survival (DFS) overall (OS) undergoing laparoscopic-assisted radical resection distal cancer.Methods/design: prospective, multicenter, randomized controlled (RCT). experiment will include randomly divided groups, experimental group control group, according proportion 1:1. The perioperative period be managed pathway, traditional management mode. An estimated 400 enrolled. main endpoint compare 3-year OS PFS between two groups.Discussion: should demonstrate superior inflammatory indexes, outcome laparoscopic assisted cancer.Our data provide evidence improves with cancer.Trial registration: Chinese Clinical Trial Registry, CHiCTR1900022438. Registered 11 April 2019